Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 10/20 | 0.53 |
| ▸ | TYK2 | P29597 | 10/20 | 0.53 |
| ▸ | JAK3 | P52333 | 10/20 | 0.53 |
| ▸ | JAK1 | P23458 | 9/20 | 0.53 |
| ▸ | AURKA | O14965 | 4/20 | 0.53 |
| ▸ | SRC | P12931 | 3/20 | 0.53 |
| ▸ | GSK3B | P49841 | 3/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.50 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.47 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.47 |
| ▸ | GSK3A | P49840 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22054016 | 1.00 | JAK2 (0.53) | JAK2TYK2JAK3JAK1AURKA | |
| SCHEMBL23878926 | 0.91 | TYK2 (0.53) | JAK2TYK2JAK3JAK1AURKA | |
| SCHEMBL22054022 | 0.91 | TYK2 (0.53) | JAK2TYK2JAK3JAK1AURKA | |
| SCHEMBL22054199 | 0.91 | AURKA (0.54) | AURKASRCGSK3BAURKBNTRK1 | |
| SCHEMBL23878992 | 0.89 | AURKA (0.59) | JAK2TYK2JAK3JAK1AURKA | |
| SCHEMBL30255661 | 0.88 | AURKA (0.58) | JAK2TYK2JAK3JAK1AURKA | |
| SCHEMBL23878843 | 0.88 | TYK2 (0.56) | JAK2TYK2JAK3JAK1AURKA | |
| SCHEMBL22054963 | 0.88 | TYK2 (0.56) | JAK2TYK2JAK3JAK1AURKA | |
| SCHEMBL22054014 | 0.85 | JAK1 (0.69) | JAK2TYK2JAK3JAK1AURKA | |
| SCHEMBL23878859 | 0.85 | JAK1 (0.69) | JAK2TYK2JAK3JAK1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| EP-3889152-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230043863-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | WEE2, WEE1, RORB | JAK2 19/4885TYK2 105/4885JAK3 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.